)
Edge1 May 2026
Making the Marlboro Man
The story of Marlboro's transformation from a women's cigarette to a global icon: one of the most effective brand repositionings in history.
MediPharm Labs
MediPharm Labs (LABS) investor relations material
MediPharm Labs Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary30 Mar, 2026
Executive summary
Full-year 2025 revenue reached CAD 45.1 million, up 8% year-over-year, driven by a 43% increase in international medical cannabis, now over 50% of total revenue.
CEO transition occurred with the CFO assuming interim CEO duties; board is searching for a permanent CEO.
Ended 2025 with a cash balance of CAD 10.8 million and virtually no debt, owning two production facilities outright.
Expanded product portfolio in Europe and Australia, including launches of new pharmaceutical-grade inhalers.
Company operates across four verticals: international medical, Canadian medical, pharmaceutical/B2B, and adult use/wellness.
Financial highlights
Q4 2025 revenue was CAD 11.1 million, down from CAD 12 million in Q4 2024 due to timing and mix in international medical.
International medical cannabis revenue was CAD 6.1 million (55% of Q4 revenue); Canadian medical cannabis revenue was CAD 3.2 million, up 8% sequentially.
Q4 gross profit was CAD 3.9 million (35% margin), up from CAD 3.6 million (30%) in Q4 2024, driven by product mix and cost reductions.
Full-year gross profit was CAD 14 million (31% margin), up from CAD 12.8 million (31%) in 2024.
Adjusted EBITDA loss for 2025 improved to CAD 1.6 million from CAD 1.9 million in 2024.
Outlook and guidance
No formal guidance provided, but priorities for 2026 include growing international medical revenue, expanding brands, and maintaining cost discipline.
Plans for continued expansion of product portfolio and geographic reach, targeting Brazil, France, and New Zealand.
Expects continued margin improvement through product mix and operational efficiency.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from MediPharm Labs
- Record gross margin and positive EBITDA driven by 87% international medical revenue growth.LABS
Q1 202523 Apr 2026 - Record revenue and near breakeven EBITDA driven by global sales and cost efficiencies.LABSQ2 20241 Feb 2026
- Q2 2025 revenue up 14% year-over-year, driven by international medical cannabis growth.LABSQ2 202523 Nov 2025
- International medical cannabis drove 17% revenue growth, with margin recovery expected ahead.LABSQ3 202517 Nov 2025
- Revenue up 15%, gross margin up 29%, and debt-free, MediPharm eyes 2025 profitability.LABSQ3 202413 Jun 2025
- Record international sales and margin gains drive MediPharm Labs near profitability.LABSQ4 20245 Jun 2025
Next MediPharm Labs earnings date
Q1 202613 May, 2026
MediPharm Labs
Next MediPharm Labs earnings date
Q1 202613 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage